All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer

Ching-Fei Li,Li-Yuan Bai,Yongkun Wei,Heng-Huan Lee,Riyao Yang,Jun Yao,Huamin Wang,Ying-Nai Wang,Wei-Chao Chang,Yi-Chun Shen,Shao-Chun Wang,Cheng-Wei Chou,Jie Fu,Jianhua Ling,Yu-Yi Chu,Chang-Fang Chiu,Michael Wang,Dihua Yu,Paul J Chiao,Han Liang,Anirban Maitra,Haoqiang Ying,Mien-Chie Hung

DOI: https://doi.org/10.1101/2024.10.20.619300

2024-10-23

Abstract:As a double-stranded RNA editing enzyme and an interferon-stimulated gene, double-stranded RNA-specific adenosine deaminase (ADAR1) suppresses interferon signaling and contributes to immunotherapy resistance. Suppression of ADAR1 overcomes immunotherapy resistance in preclinical models, but has not yet been translated to clinical settings. By conducting a screening of a subset of the FDA-approved drugs, we found that all-trans retinoic acid (ATRA, also known as tretinoin) caused ADAR1 protein degradation through ubiquitin-proteasome pathways and concomitantly increased PD-L1 expression in pancreatic and breast cancers. In addition, the combination of ATRA and PD-1 blockade reprogrammed the tumor microenvironment and unleashed antitumor immunity and thereby impeded tumor growth in pancreatic cancer mouse models. In a pilot clinical trial, a higher dose of ATRA plus the anti-PD-1 antibody nivolumab prolonged median overall survival in patients with chemotherapy-resistant pancreatic cancer compared to a lower dose of the same regimen. In this study, ATRA was the first drug to be found to cause ADAR1 degradation. We propose translation of a promising 2-pronged antitumor strategy using ATRA and nivolumab to convert immunologically cold into hot tumors susceptible to immune checkpoint blockade.

Cancer Biology

What problem does this paper attempt to address?

The problem this paper attempts to address is: how to improve the treatment efficacy of pancreatic cancer by suppressing ADAR1 expression and enhancing immune checkpoint blockade therapy (such as PD-1 blockade).

Specifically, the researchers found that all-trans retinoic acid (ATRA) can induce the degradation of ADAR1 protein while simultaneously increasing the expression of PD-L1. The combination therapy of ATRA and PD-1 blockers (such as nivolumab) can reprogram the tumor microenvironment, activate anti-tumor immune responses, thereby inhibiting the growth of pancreatic cancer. Furthermore, clinical trial results show that higher doses of ATRA combined with nivolumab can significantly extend the median overall survival of patients with chemotherapy-resistant pancreatic cancer.

In summary, this study aims to explore a new combination therapy method to convert "cold" tumors into "hot" tumors, thereby improving the efficacy of immune checkpoint blockade therapy in pancreatic cancer.